Multiple sclerosis
Disease that damages the myelin sheaths around nerves
Follow Multiple sclerosis on Notably News to receive short updates to your email — rarely!
We include updates on Transverse myelitis, Acute disseminated encephalomyelitis, Lhermitte's sign, MOG antibody disease, Speedbumps: Flooring It Through Hollywood, Hilary and Jackie, X+Y, Uhthoff's phenomenon, Fingolimod, McDonald criteria, MS Readathon, Lesional demyelinations of the central nervous system, Swank diet, Inflammatory demyelinating diseases of the central nervous system, Calcium 2-aminoethylphosphate, Expanded Disability Status Scale ... and more.
| 2025 |
Stephen L. Hauser
Stephen L. Hauser shared the Breakthrough Prize in Life Sciences with Alberto Ascherio for transforming the understanding and treatment of multiple sclerosis.
|
| 2024 | Scientists published research tracing MS-risk gene variants to ancient migration from the Yamnaya culture, discovering that these genetic variants originally protected cattle herders from animal diseases, but now contribute to increased MS risk due to modern lifestyles and improved hygiene. |
| 2024 |
Multiple sclerosis drug pipeline
Expected FDA submission for tolebrutinib.
|
| 2024 |
Signs and symptoms of multiple sclerosis
A research study suggested that fatigue in early Relapsing-Remitting Multiple Sclerosis (RRMS) was not driven by neuroinflammation or neurodegeneration measurable by current structural MRI techniques.
|
| 2024 | The Multiple Sclerosis Society became a member of the Neurological Alliance and the Progressive MS Alliance, expanding its collaborative efforts in multiple sclerosis research and advocacy. |
| 2024 | Given the 'Giants of Multiple Sclerosis Award' by the Consortium of MS Centers, recognizing his lifetime work in multiple sclerosis research. |
| September 2024 | Ocrelizumab/hyaluronidase was approved for medical use in the United States. |
| 2023 |
Signs and symptoms of multiple sclerosis
A study investigated the impact of fatigue on multiple sclerosis patients, finding that improving fatigue was the most valued attribute of MS therapy. Participants indicated they would accept six additional relapses in 2 years and a decrease of 7 years in disease progression time to improve cognitive or physical fatigue from 'quite a bit of difficulty' to 'no difficulty'.
|
| 2023 | Ann and Mitt Romney made a $2.5M gift to establish the Howard L. Weiner Distinguished Chair in Neurology at Brigham and Women's Hospital. |
| April 2023 |
Fingolimod
The U.S. Supreme Court declined to hear Novartis's request to revive a key patent on Gilenya that had been previously invalidated by a lower court.
|
| 2022 | Nearly one million people in the United States were diagnosed with Multiple Sclerosis (MS). |
| 2022 | A scientific review found that nabiximols (a cannabis-based medication containing THC and CBD) can potentially reduce short-term spasticity severity in multiple sclerosis patients, though with potential neurological side effects. |
| 2022 | Began human trials of nasal immune therapy for MS, Alzheimer's disease, and ALS, using an anti-CD3 monoclonal antibody to induce regulatory T cells. |
| 2022 | 'The Brain Under Siege' was named a finalist for The Next Generation Indie Book Awards. |
| December 2022 |
Multiple sclerosis drug pipeline
Ublituximab (Briumvi) was approved for medical use in the United States for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive multiple sclerosis.
|
| December 2022 |
Management of multiple sclerosis
Ublituximab (Briumvi) was approved for medical use in the United States.
|
| October 2022 |
Fingolimod
The Supreme Court rejected Novartis's request to block the launch of generic versions of Gilenya in the United States.
|
| 2021 | Ponesimod was approved for management of CIS, relapsing MS, and SPMS in the U.S., and relapsing-remitting MS in Europe. |
| 2021 |
Multiple sclerosis drug pipeline
First patient dosing expected in the second half of 2021 for the ENSURE-1 and ENSURE-2 phase 3 trials of IMU-838.
|
| 2021 | The documentary about Selma Blair won The Cinema for Peace Award on Global Health, recognizing the film's powerful portrayal of her health journey and personal experiences. |
| 2021 | Published 'The Brain Under Siege', a book that explores the brain using a metaphorical crime scene approach to understanding causes and potential cures. |
| 2021 | Initiated human trials of a nasal vaccine for Alzheimer's disease, designed to trigger blood monocytes to clear amyloid from the brain. |
| November 2021 |
Diroximel fumarate
Diroximel fumarate was approved for medical use in the European Union, expanding its availability as a treatment for multiple sclerosis patients in the region.
|
| October 21 2021 | Documentary film began streaming on Discovery+ platform. |
| October 15 2021 | Documentary film received a limited theatrical release. |
| September 2021 |
Diroximel fumarate
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Vumerity (diroximel fumarate) to treat adults with relapsing remitting multiple sclerosis.
|
| July 2021 |
Multiple sclerosis drug pipeline
FDA granted an investigational new drug (IND) application for the phase 3 ENSURE program to evaluate IMU-838 in relapsing-remitting multiple sclerosis (RRMS) patients.
|
| July 2021 |
Multiple sclerosis drug pipeline
Immunic received FDA clearance for a separate IND application for the phase 2 CALLIPER trial of IMU-838 in progressive multiple sclerosis patients.
|
| March 2021 |
Management of multiple sclerosis
Ponesimod (Ponvory) was approved for medical use in the United States.
|
| March 26 2021 |
Management of multiple sclerosis
The U.S. Food and Drug Administration (FDA) authorized marketing of the Portable Neuromodulation Stimulator (PoNS), a novel device for short-term treatment of gait deficit in multiple sclerosis patients. This non-implantable neuromuscular tongue stimulator is intended for patients 22 years and older, designed to be used as an adjunct to a supervised therapeutic exercise program by prescription.
|
| March 16 2021 | Documentary 'Introducing, Selma Blair' world premiered at South by Southwest film festival, winning the Special Jury Award for Exceptional Intimacy in Storytelling in the Documentary Feature Competition. |
| 2020 | Ozanimod was approved for management of CIS, relapsing MS, and SPMS in the U.S., and relapsing-remitting MS in Europe. |
| 2020 | Global prevalence of multiple sclerosis reached approximately 2.8 million people, highlighting the significant worldwide impact of this neurological disorder. |
| 2020 |
MOG antibody disease
Multiple studies conducted to investigate the distinctive characteristics of MOG antibody disease (MOGAD) lesions, revealing significant differences from multiple sclerosis (MS) in terms of CNS topographical distribution, demyelination type, and inflammatory response.
|
| 2020 | The Foundation for Neurologic Diseases established the Indirawati Kuchroo and Charlotte Weiner Distinguished Chair in Neuroimmunology with a $2M gift to Brigham and Women's Hospital. |
| April 2020 |
Multiple sclerosis drug pipeline
Bafiertam, the active principal monomethyl fumarate, was approved as a multiple sclerosis medication.
|
| April 2020 |
Monomethyl fumarate
Monomethyl fumarate (Bafiertam) received approval for medical use in the United States for treating relapsing forms of multiple sclerosis in adults.
|
| April 2020 |
Management of multiple sclerosis
Monomethyl fumarate (Bafiertam) was approved in the United States for treating relapsing forms of multiple sclerosis.
|
| March 2020 |
Multiple sclerosis drug pipeline
Ozanimod (Zeposia) was approved by the FDA as an oral treatment for multiple sclerosis.
|
| March 2020 |
Management of multiple sclerosis
Ozanimod (Zeposia) was approved in the United States for treating relapsing multiple sclerosis in adults.
|
| March 2020 |
Management of multiple sclerosis
Ozanimod was approved by the FDA as a disease-modifying treatment for multiple sclerosis.
|
| January 2020 |
Fingolimod
A panel of judges at the Court of Appeal for the Federal Circuit questioned the validity of the last remaining orange book patent protecting Gilenya.
|
| January 2020 |
Siponimod
Siponimod was approved in the European Union for treating adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
|
| 2019 |
Management of multiple sclerosis
Siponimod and cladribine were approved in the United States for treating secondary progressive multiple sclerosis.
|
| 2019 | Tilos Therapeutics was acquired by Merck & Co, marking a significant milestone in the company's development of innovative cancer treatment approaches. |
| 2019 | Received the American Brain Foundation Award, further acknowledging his significant contributions to neuroscience research. |
| December 2019 |
Fingolimod
Generic fingolimod was approved in the United States for treating relapsing forms of multiple sclerosis in adults, with FDA approvals granted to HEC Pharm Co. Limited, Biocon Limited, and Sun Pharmaceutical Industries Limited.
|
| October 2019 |
Siponimod
Siponimod was approved for medical use in Australia.
|
| October 2019 |
Multiple sclerosis drug pipeline
Diroximel fumarate (Vumerity) was approved by the FDA as a new multiple sclerosis treatment.
|
|
We are only showing the most recent entries for this topic. |
|
This contents of the box above is based on material from the Wikipedia articles Fingolimod, Multiple Sclerosis Society of Great Britain, Signs and symptoms of multiple sclerosis, Introducing, Selma Blair, Diroximel fumarate, Multiple sclerosis, Stephen L. Hauser, MOG antibody disease, Monomethyl fumarate, Siponimod, Multiple sclerosis drug pipeline, Howard L. Weiner & Management of multiple sclerosis, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.